WO2016016769A1 - A process for the preparation of palbociclib - Google Patents

A process for the preparation of palbociclib Download PDF

Info

Publication number
WO2016016769A1
WO2016016769A1 PCT/IB2015/055528 IB2015055528W WO2016016769A1 WO 2016016769 A1 WO2016016769 A1 WO 2016016769A1 IB 2015055528 W IB2015055528 W IB 2015055528W WO 2016016769 A1 WO2016016769 A1 WO 2016016769A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
trimethylsilyl
dimethylsilyl
butyldimethylsilyl
Prior art date
Application number
PCT/IB2015/055528
Other languages
French (fr)
Other versions
WO2016016769A8 (en
Inventor
Vipin Tyagi
Kallimulla Mohammad
Bishwa Prakash Rai
Mohan Prasad
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Priority to EP15826397.0A priority Critical patent/EP3174878A4/en
Priority to US15/500,616 priority patent/US20170217962A1/en
Publication of WO2016016769A1 publication Critical patent/WO2016016769A1/en
Publication of WO2016016769A8 publication Critical patent/WO2016016769A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Definitions

  • the present invention relates to a process for the preparation of palbociclib.
  • Palbociclib chemically is 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(l-piperazinyl)-2- pyridinyl]amino]pyrido 2,3-d]pyrimidin-7(8H)-one, represented by the Formula I.
  • U.S. Patent No. 6,936,612 discloses palbociclib and a process for the preparation of its hydrochloride salt.
  • U.S. Patent No. 7,781,583 discloses a process for the preparation of palbociclib, wherein 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one of Formula II
  • U.S. Patent No. 7,863,278 discloses polymorphs of various salts of palbociclib and processes for their preparation.
  • the present invention relates to a process for the preparation of palbociclib.
  • room temperature refers to a temperature in the range of 25°C to 35°C.
  • a first aspect of the present invention provides a process for the preparation of a compound of Formula IV,
  • R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl
  • R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl
  • a second aspect of the present invention provides a process for the preparation of palbociclib of Formula I,
  • R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl with a compound of Formula III
  • R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl; and b) converting the compound of Formula IV to palbociclib of Formula I.
  • a third aspect of the present invention provides a process for the preparation of a compound of Formula II
  • R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl with a compound of Formula III
  • R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl; and b) intramolecular cyclization of the compound of Formula IV to give a
  • a fourth aspect of the present invention provides a process for the preparation of palbociclib of Formula I
  • R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl with a compound of Formula III
  • R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl
  • the compound of Formula V may be prepared by any method known in the art, for example, the method described in U.S. Patent No. 7, 126,025, or by the method as described herein.
  • the compound of Formula III may be prepared by any method known in the art, for example, the method described in U.S. Patent No. 7,781,583.
  • the compound of Formula III is reacted with the compound of Formula V in the presence of the palladium catalyst, the base, and optionally the ligand to give the compound of Formula IV in a solvent.
  • the compound of Formula V may be reacted with the compound of Formula III after isolation from the reaction mixture in which it is formed.
  • the reaction mixture containing the compound of Formula V may be used for the reaction with the compound of Formula III.
  • the base is an organic base or an inorganic base.
  • organic bases include triethylamine, diisopropylethylamine, and tributylamine.
  • inorganic bases include potassium carbonate, sodium carbonate, and lithium carbonate.
  • the palladium catalyst is selected from the group consisting of
  • the ligand is selected from the group consisting of tri-o-tolylphosphine, triphenylphosphine, and tri-i-butylphosphine.
  • the solvent is selected from the group consisting of ethers, halogenated hydrocarbons, alcohols, and esters.
  • ether solvents include tetrahydrofuran, 1,4-dioxane, diisopropylether, and methyl fert-butyl ether.
  • halogenated hydrocarbon solvents include dichloromethane, dichloroethane, chloroform, and carbon tetrachloride.
  • Examples of alcohol solvents include methanol, ethanol, n-propanol, isopropanol, and n-butanol.
  • ester solvents include ethyl acetate and butyl acetate.
  • the reaction of the compound of Formula III with the compound of Formula V is carried out for from about 15 hours to about 30 hours, for example, from about 18 hours to about 24 hours.
  • the reaction of the compound of Formula III with the compound of Formula V is carried out at a temperature of from about 50°C to about 90°C, for example, from about 70°C to about 80°C.
  • the compound of Formula IV may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, or recrystallization.
  • the compound of Formula IV may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, air drying, or agitated thin film drying.
  • the intramolecular cyclization of the compound of Formula IV to give the compound of Formula II is carried out in the presence of an acid anhydride or an acid chloride.
  • acid anhydrides include acetic anhydride, propionic anhydride, butyric anhydride, trifluoroacetic anhydride, and trifluoromethanesulfonic anhydride.
  • acid chlorides include acetyl chloride and ethanoyl chloride.
  • the intramolecular cyclization of the compound of Formula IV may be carried out after isolation from the reaction mixture in which it is formed. Alternatively, the reaction mixture containing the compound of Formula IV may be used for this step.
  • the intramolecular cyclization of the compound of Formula IV is carried out for from about 1 hour to about 6 hours, for example, from about 2 hours to about 3 hours.
  • the intramolecular cyclization of the compound of Formula IV is carried out at a temperature of from about 50°C to about 90°C, for example, from about 70°C to about 80°C.
  • the compound of Formula II may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, or recrystallization.
  • the compound of Formula II may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, air drying, or agitated thin film drying.
  • the compound of Formula II is converted to palbociclib of Formula I by processes known in the art, for example, as disclosed in U.S. Patent No. 7,781,583. While the present invention has been described in terms of its specific aspects and embodiments, certain modifications and equivalents will be apparent to those skilled in the art, and are intended to be included within the scope of the present invention.
  • Step a Preparation of trimethylsilyl (2£)-but-2-enoate (Formula V, when R is trimethylsilyl)
  • Crotonic acid (18.68 g) was taken in dichloromethane (80 mL) at room temperature
  • Trimethylsilyl (2£)-but-2-enoate (obtained from step a) and diisopropylethylamine (52 mL) were added to a solution of 5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine (20 g, Formula III) in tetrahydrofuran (100 mL) at room temperature under a nitrogen atmosphere.
  • the reaction system was degassed under vacuum and then flushed with nitrogen; this evacuation procedure was repeated three times.
  • Trans- dichlorobis(acetonitrile) palladium (II) (0.970 g) followed by the addition of tri-o- tolylphosphine (0.770 g) was added to the reaction mixture under a nitrogen atmosphere.
  • reaction system was again degassed under vacuum and then flushed with nitrogen; this evacuation procedure was repeated three times.
  • the reaction mixture was heated at 75°C to 80°C overnight.
  • the progress of the reaction was monitored by thin layer chromatography (TLC) (60% ethyl acetate/toluene).
  • TLC thin layer chromatography
  • Trans-dichlorobis(acetonitrile) palladium (II) (0.725 g) was again added followed by the addition of tri-o-tolylphosphine (0.725 g) was again added followed by the addition of tri-o-tolylphosphine (0.725 g) to the reaction mixture at 75°C to 80°C.
  • the reaction mixture was heated at 75°C to 80°C for 4 hours.
  • Trimethylsilyl (2£)-but-2-enoate (obtained from step a) and diisopropylethylamine (26.5 mL) were added to a solution of 5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine (Formula III, 10 g) in tetrahydrofuran (50 mL) at room temperature under a nitrogen atmosphere.
  • the reaction system was degassed under vacuum and then flushed with nitrogen; this evacuation procedure was repeated three times.
  • Trans- dichlorobis(acetonitrile) palladium (II) (1.39 g) followed by the addition of tri-o- tolylphosphine (1.1 g) was added to the reaction mixture under a nitrogen atmosphere.
  • the reaction system was degassed under vacuum and then flushed with nitrogen; this evacuation procedure was repeated three times.
  • the reaction mixture was heated at 75 °C to 80°C overnight.
  • acetic anhydride (20 mL) was added, and then the mixture was stirred at 75°C to 80°C for 3 hours.
  • the reaction mixture was cooled to room temperature.
  • Dichloromethane (50 mL) and IN hydrochloric acid (50 mL) were added, and then the mixture was stirred for 10 minutes.
  • the layers were separated and the aqueous layer was re-extracted with dichloromethane (20 mL) and separated.
  • the combined organic layers were washed with a 5% sodium bicarbonate solution (200 mL) at room temperature.
  • the organic layer was separated and activated carbon (1 g) was added to the mixture. The mixture was stirred for 20 minutes at room temperature. The mixture was filtered through a Hyflo ® bed and then washed with dichloromethane (20 mL). The organic layer was evaporated under vacuum to obtain a residue. Isopropyl alcohol (40 mL) was added to the residue and then the solvent was evaporated under reduced pressure until 20 mL of isopropyl alcohol remained. Isopropyl alcohol (20 mL) was again added to the mixture and then the solvent was evaporated under reduced pressure until 20 mL of isopropyl alcohol remained. The mixture was stirred for 3 hours at room temperature. The product was filtered and washed with isopropyl alcohol (10 mL), and then dried under vacuum at 45°C to obtain the title compound.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a process for the preparation of palbociclib utilizing a silyl-protected crotonic acid derivative to produce a silyl-protected 5-(1-methyl-3 carboxy-prop-1-en-1-yl)-2-chloro-piperazine followed by intramolecular cyclization of the compound the piperazine intermediate to produce 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one which is then converted to palbociclib.

Description

A PROCESS FOR THE PREPARATION OF PALBOCICLIB
Field of the Invention
The present invention relates to a process for the preparation of palbociclib.
Background of the Invention
Palbociclib chemically is 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(l-piperazinyl)-2- pyridinyl]amino]pyrido 2,3-d]pyrimidin-7(8H)-one, represented by the Formula I.
Figure imgf000002_0001
Formula I
U.S. Patent No. 6,936,612 discloses palbociclib and a process for the preparation of its hydrochloride salt.
U.S. Patent No. 7,781,583 discloses a process for the preparation of palbociclib, wherein 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one of Formula II
Figure imgf000002_0002
Formula II
prepared by reacting 5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine of Formula III
Figure imgf000002_0003
Formula III
with crotonic acid. U.S. Patent No. 7,863,278 discloses polymorphs of various salts of palbociclib and processes for their preparation.
Summary of the Invention
The present invention relates to a process for the preparation of palbociclib.
Detailed Description of the Invention
The term "about," as used herein, refers to any value which lies within the range defined by a number up to ±10% of the value.
The term "room temperature," as used herein, refers to a temperature in the range of 25°C to 35°C.
A first aspect of the present invention provides a process for the preparation of a compound of Formula IV,
Figure imgf000003_0001
Formula IV
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl
comprising reacting a crotonic acid derivative of Formula V
Figure imgf000003_0002
Formula V
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl
with a compound of Formula III
Figure imgf000004_0001
Formula III
in the presence of a palladium catalyst, a base, and optionally a ligand to give a compound of Formula IV.
A second aspect of the present invention provides a process for the preparation of palbociclib of Formula I,
Figure imgf000004_0002
Formula I
a) reacting a crotonic acid derivative of Formula V,
Figure imgf000004_0003
Formula V
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl with a compound of Formula III
Figure imgf000004_0004
Formula III in the presence of a palladium catalyst, a base, and optionally a ligand to give a compound of Formula IV
Figure imgf000005_0001
Formula IV
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl; and b) converting the compound of Formula IV to palbociclib of Formula I.
A third aspect of the present invention provides a process for the preparation of a compound of Formula II
Figure imgf000005_0002
Formula II
a) reacting a crotonic acid derivative of Formula V,
Figure imgf000005_0003
Formula V
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl with a compound of Formula III
Figure imgf000006_0001
Formula III
in the presence of a palladium catalyst, a base, and optionally a ligand to give a compound of Formula IV,
Figure imgf000006_0002
Formula IV
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl; and b) intramolecular cyclization of the compound of Formula IV to give a
compound of Formula II.
A fourth aspect of the present invention provides a process for the preparation of palbociclib of Formula I
Figure imgf000006_0003
Formula I
comprising:
a) reacting a crotonic acid derivative of Formula V,
Figure imgf000007_0001
Formula V
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl with a compound of Formula III
Figure imgf000007_0002
Formula III
in the presence of a palladium catalyst, a base, and optionally a ligand to give a compound of Formula IV
Figure imgf000007_0003
Formula IV
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl;
intramolecular cyclization of the compound of Formula IV to give a compound of Formula II; and
Figure imgf000007_0004
Formula II
converting the compound of Formula II to palbociclib of Formula I. The compound of Formula V may be prepared by any method known in the art, for example, the method described in U.S. Patent No. 7, 126,025, or by the method as described herein.
The compound of Formula III may be prepared by any method known in the art, for example, the method described in U.S. Patent No. 7,781,583.
The compound of Formula III is reacted with the compound of Formula V in the presence of the palladium catalyst, the base, and optionally the ligand to give the compound of Formula IV in a solvent.
The compound of Formula V may be reacted with the compound of Formula III after isolation from the reaction mixture in which it is formed. Alternatively, the reaction mixture containing the compound of Formula V may be used for the reaction with the compound of Formula III.
The base is an organic base or an inorganic base. Examples of organic bases include triethylamine, diisopropylethylamine, and tributylamine. Examples of inorganic bases include potassium carbonate, sodium carbonate, and lithium carbonate.
The palladium catalyst is selected from the group consisting of
tetrakis(triphenylphosphine)palladium (0), palladium acetate, palladium chloride, and trans-dichlorobis(acetonitrile)palladium (II) .
The ligand is selected from the group consisting of tri-o-tolylphosphine, triphenylphosphine, and tri-i-butylphosphine.
The solvent is selected from the group consisting of ethers, halogenated hydrocarbons, alcohols, and esters. Examples of ether solvents include tetrahydrofuran, 1,4-dioxane, diisopropylether, and methyl fert-butyl ether. Examples of halogenated hydrocarbon solvents include dichloromethane, dichloroethane, chloroform, and carbon tetrachloride. Examples of alcohol solvents include methanol, ethanol, n-propanol, isopropanol, and n-butanol. Examples of ester solvents include ethyl acetate and butyl acetate.
The reaction of the compound of Formula III with the compound of Formula V is carried out for from about 15 hours to about 30 hours, for example, from about 18 hours to about 24 hours. The reaction of the compound of Formula III with the compound of Formula V is carried out at a temperature of from about 50°C to about 90°C, for example, from about 70°C to about 80°C.
The compound of Formula IV may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, or recrystallization. The compound of Formula IV may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, air drying, or agitated thin film drying.
The intramolecular cyclization of the compound of Formula IV to give the compound of Formula II is carried out in the presence of an acid anhydride or an acid chloride.
Examples of acid anhydrides include acetic anhydride, propionic anhydride, butyric anhydride, trifluoroacetic anhydride, and trifluoromethanesulfonic anhydride. Examples of acid chlorides include acetyl chloride and ethanoyl chloride.
The intramolecular cyclization of the compound of Formula IV may be carried out after isolation from the reaction mixture in which it is formed. Alternatively, the reaction mixture containing the compound of Formula IV may be used for this step.
The intramolecular cyclization of the compound of Formula IV is carried out for from about 1 hour to about 6 hours, for example, from about 2 hours to about 3 hours.
The intramolecular cyclization of the compound of Formula IV is carried out at a temperature of from about 50°C to about 90°C, for example, from about 70°C to about 80°C.
The compound of Formula II may optionally be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, or recrystallization. The compound of Formula II may be dried using conventional techniques, for example, drying, drying under vacuum, spray drying, air drying, or agitated thin film drying.
The compound of Formula II is converted to palbociclib of Formula I by processes known in the art, for example, as disclosed in U.S. Patent No. 7,781,583. While the present invention has been described in terms of its specific aspects and embodiments, certain modifications and equivalents will be apparent to those skilled in the art, and are intended to be included within the scope of the present invention.
Method
Chromatographic purity was determined by HPLC using an Agilent® Model 1200; the column used was an ACE® C18-PFP (150 x 4.6 nm).
The following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
EXAMPLES
Preparation of 2-chloro-8 -cyclopentyl-5 -methyl-8H-pyrido Γ2.3 - lpyrimidin-7-one (Formula II)
Step a: Preparation of trimethylsilyl (2£)-but-2-enoate (Formula V, when R is trimethylsilyl)
Crotonic acid (18.68 g) was taken in dichloromethane (80 mL) at room
temperature to obtain a solution. Hexamethyldisilazane (HMDS) (21 g) followed by imidazole (0.4 g) was added to the solution at room temperature under stirring. The reaction mixture was refluxed for 2 hours. Dichloromethane was recovered completely under vacuum at 45°C. Dichloromethane (200 mL) was again added to the reaction mixture, and then recovered completely under vacuum at 45°C. The colorless liquid obtained was taken as such for next step.
Step b: Preparation of 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-i/|pyrimidin-7- one (Formula II)
Method A
Trimethylsilyl (2£)-but-2-enoate (obtained from step a) and diisopropylethylamine (52 mL) were added to a solution of 5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine (20 g, Formula III) in tetrahydrofuran (100 mL) at room temperature under a nitrogen atmosphere. The reaction system was degassed under vacuum and then flushed with nitrogen; this evacuation procedure was repeated three times. Trans- dichlorobis(acetonitrile) palladium (II) (0.970 g) followed by the addition of tri-o- tolylphosphine (0.770 g) was added to the reaction mixture under a nitrogen atmosphere. The reaction system was again degassed under vacuum and then flushed with nitrogen; this evacuation procedure was repeated three times. The reaction mixture was heated at 75°C to 80°C overnight. The progress of the reaction was monitored by thin layer chromatography (TLC) (60% ethyl acetate/toluene). Trans-dichlorobis(acetonitrile) palladium (II) (0.725 g) was again added followed by the addition of tri-o-tolylphosphine (0.725 g) to the reaction mixture at 75°C to 80°C. The reaction mixture was heated at 75°C to 80°C for 4 hours. After completion of the reaction, acetic anhydride (17 mL) was added, and then the mixture was stirred at 75°C to 80°C for 3 hours. The reaction mixture was cooled to room temperature. Dichloromethane (100 mL) and IN hydrochloric acid (100 mL) were added and then the mixture was stirred for 10 minutes. The layers were separated and the aqueous layer was re-extracted with dichloromethane (40 mL) and separated. The combined organic layers were washed with a 5% sodium bicarbonate solution (200 mL) at room temperature. The organic layer was separated and activated carbon (2 g) was added to the mixture. The mixture was stirred for 20 minutes at room temperature. The mixture was filtered through a Hyflo® bed and then washed with dichloromethane (40 mL). The organic layer was evaporated under vacuum to obtain a residue. Isopropyl alcohol (80 mL) was added to the residue and the solvent was evaporated under reduced pressure until 40 mL of isopropyl alcohol remained. Isopropyl alcohol (40 mL) was again added to the mixture, and then the solvent was evaporated under reduced pressure until 20 mL of isopropyl alcohol remained. The mixture was stirred for 3 hours at room temperature. The product was filtered, thenwashed with isopropyl alcohol (20 mL), and then dried under vacuum at 45°C to obtain the title compound.
Yield: 0.535% w/w
Chromatographic purity: 99.51%
Method B
Trimethylsilyl (2£)-but-2-enoate (obtained from step a) and diisopropylethylamine (26.5 mL) were added to a solution of 5-bromo-2-chloro-N-cyclopentylpyrimidin-4-amine (Formula III, 10 g) in tetrahydrofuran (50 mL) at room temperature under a nitrogen atmosphere. The reaction system was degassed under vacuum and then flushed with nitrogen; this evacuation procedure was repeated three times. Trans- dichlorobis(acetonitrile) palladium (II) (1.39 g) followed by the addition of tri-o- tolylphosphine (1.1 g) was added to the reaction mixture under a nitrogen atmosphere. The reaction system was degassed under vacuum and then flushed with nitrogen; this evacuation procedure was repeated three times. The reaction mixture was heated at 75 °C to 80°C overnight. After completion of the reaction, acetic anhydride (20 mL) was added, and then the mixture was stirred at 75°C to 80°C for 3 hours. The reaction mixture was cooled to room temperature. Dichloromethane (50 mL) and IN hydrochloric acid (50 mL) were added, and then the mixture was stirred for 10 minutes. The layers were separated and the aqueous layer was re-extracted with dichloromethane (20 mL) and separated. The combined organic layers were washed with a 5% sodium bicarbonate solution (200 mL) at room temperature. The organic layer was separated and activated carbon (1 g) was added to the mixture. The mixture was stirred for 20 minutes at room temperature. The mixture was filtered through a Hyflo® bed and then washed with dichloromethane (20 mL). The organic layer was evaporated under vacuum to obtain a residue. Isopropyl alcohol (40 mL) was added to the residue and then the solvent was evaporated under reduced pressure until 20 mL of isopropyl alcohol remained. Isopropyl alcohol (20 mL) was again added to the mixture and then the solvent was evaporated under reduced pressure until 20 mL of isopropyl alcohol remained. The mixture was stirred for 3 hours at room temperature. The product was filtered and washed with isopropyl alcohol (10 mL), and then dried under vacuum at 45°C to obtain the title compound.
Yield: 0.46% w/w
Chromatographic purity: 98.1%

Claims

We Claim:
1. A process for the preparation of a compound of Formula IV
Figure imgf000013_0001
Formula IV
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl
comprising reacting a crotonic acid derivative of Formula V
Figure imgf000013_0002
Formula V
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl
with a compound of Formula III
Figure imgf000013_0003
Formula III
in the presence of a palladium catalyst, a base, and optionally a ligand to give a compound of Formula IV. A process for the reparation of palbociclib of Formula I,
Figure imgf000014_0001
Formula I
comprising:
a) reacting a crotonic acid derivative of Formula V
Figure imgf000014_0002
Formula V
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl with a compound of Formula III
Figure imgf000014_0003
Formula III
in the presence of a palladium catalyst, a base, and optionally a ligand to give a compound of Formula IV
Figure imgf000014_0004
Formula IV wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl; and b) converting the compound of Formula IV to palbociclib of Formula I.
A process for the preparation of a compound of Formula II
Figure imgf000015_0001
Formula II
comprising:
a) reacting a crotonic acid derivative of Formula V
Figure imgf000015_0002
Formula V
wherein R is trimethylsilyl, dimethylsilyl, or fer -butyldimethylsilyl with a compound of Formula III
Figure imgf000015_0003
Formula III
in the presence of a palladium catalyst, a base, and optionally a ligand to give a compound of Formula IV
Figure imgf000016_0001
Formula IV
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl; and b) intramolecular cyclization of the compound of Formula IV to give a compound of Formula II.
A process for the reparation of palbociclib of Formula I
Figure imgf000016_0002
Formula I
comprising:
a) reacting a crotonic acid derivative of Formula V
Figure imgf000016_0003
Formula V
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl with a compound of Formula III
Figure imgf000017_0001
Formula III
in the presence of a palladium catalyst, a base, and optionally a ligand to give a compound of Formula IV
Figure imgf000017_0002
Formula IV
wherein R is trimethylsilyl, dimethylsilyl, or fert-butyldimethylsilyl;
b) intramolecular cyclization of the compound of Formula IV to give a
compound of Formula II; and
Figure imgf000017_0003
Formula II
c) converting the compound of Formula II to palbociclib of Formula I.
5. The process according to claim 1, 2, 3, or 4, wherein the compound of Formula III is reacted with the compound of Formula V to give the compound of Formula IV in a solvent.
6. The process according to claim 1, 2, 3, or 4, wherein the palladium catalyst is selected from the group consisting of tetrakis(triphenylphosphine) palladium (0), palladium acetate, palladium chloride, and trans-dichlorobis(acetonitrile) palladium (II).
7. The process according to claim 1, 2, 3, or 4, wherein the base is an organic base or an inorganic base.
8. The process according to claim 7, wherein the organic base is selected from the group consisting of triethylamine, diisopropylethylamine, and tributylamine, and the inorganic base is selected from the group consisting of potassium carbonate, sodium carbonate, and lithium carbonate.
9. The process according to claim 1, 2, 3, or 4, wherein the ligand is selected from the group consisting of tri-o-tolylphosphine, triphenylphosphine, and tri-7-butylphosphine. 10. The process according to claim 5, wherein the solvent is selected from the group consisting of ethers, halogenated hydrocarbons, alcohols, and esters.
11. The process according to claim 3 or 4, wherein the intramolecular cyclization of the compound of Formula IV to give the compound of Formula II is carried out in the presence of an acid anhydride or an acid chloride.
12. The process according to claim 11, wherein the acid anhydride is selected from the group consisting of acetic anhydride, propionic anhydride, butyric anhydride, trifluoroacetic anhydride, and trifluoromethanesulfonic anhydride, and the acid chloride is selected from the group consisting of acetyl chloride and ethanoyl chloride.
PCT/IB2015/055528 2014-07-31 2015-07-21 A process for the preparation of palbociclib WO2016016769A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP15826397.0A EP3174878A4 (en) 2014-07-31 2015-07-21 A process for the preparation of palbociclib
US15/500,616 US20170217962A1 (en) 2014-07-31 2015-07-21 A process for the preparation of palbociclib

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2154DE2014 2014-07-31
IN2154/DEL/2014 2014-07-31

Publications (2)

Publication Number Publication Date
WO2016016769A1 true WO2016016769A1 (en) 2016-02-04
WO2016016769A8 WO2016016769A8 (en) 2016-03-24

Family

ID=55216823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/055528 WO2016016769A1 (en) 2014-07-31 2015-07-21 A process for the preparation of palbociclib

Country Status (3)

Country Link
US (1) US20170217962A1 (en)
EP (1) EP3174878A4 (en)
WO (1) WO2016016769A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108017630A (en) * 2016-10-31 2018-05-11 上海创诺制药有限公司 A kind of preparation method of small specific surface product Pa Boxini free alkalis
WO2019224194A1 (en) 2018-05-24 2019-11-28 Synthon B.V. A process for making palbociclib

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149001A1 (en) * 2002-01-22 2003-08-07 Mark Barvian 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US20080021037A1 (en) * 2003-07-11 2008-01-24 Pfizer Inc. Isethionate salt of a selective cdk4 inhibitor
WO2008032157A2 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
CN104447739A (en) * 2014-11-07 2015-03-25 郑州泰基鸿诺药物科技有限公司 Deuterated palbociclib derivative, and preparation method and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149001A1 (en) * 2002-01-22 2003-08-07 Mark Barvian 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US20080021037A1 (en) * 2003-07-11 2008-01-24 Pfizer Inc. Isethionate salt of a selective cdk4 inhibitor
WO2008032157A2 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
CN104447739A (en) * 2014-11-07 2015-03-25 郑州泰基鸿诺药物科技有限公司 Deuterated palbociclib derivative, and preparation method and application thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108017630A (en) * 2016-10-31 2018-05-11 上海创诺制药有限公司 A kind of preparation method of small specific surface product Pa Boxini free alkalis
CN108017630B (en) * 2016-10-31 2022-10-11 上海创诺制药有限公司 Preparation method of small-specific-surface-area palbociclib free base
WO2019224194A1 (en) 2018-05-24 2019-11-28 Synthon B.V. A process for making palbociclib
EP4289844A2 (en) 2018-05-24 2023-12-13 Synthon B.V. A process for making palbociclib
US11858928B2 (en) 2018-05-24 2024-01-02 Synthon B.V. Process for making palbociclib

Also Published As

Publication number Publication date
EP3174878A1 (en) 2017-06-07
US20170217962A1 (en) 2017-08-03
WO2016016769A8 (en) 2016-03-24
EP3174878A4 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
US8759515B2 (en) Process for the preparation of tenofovir disoproxil fumarate
US20170129895A1 (en) Amorphous form of baricitinib
EP3136857A1 (en) Crystalline form of baricitinib
EP3174878A1 (en) A process for the preparation of palbociclib
EP1870411B1 (en) Process for the preparation and purification of valgancyclovir
EP3010926B1 (en) Alkylation with an alkyl fluoroalkyl sulfonate
CA2828829A1 (en) Regioselective acylation of rapamycin at the c-42 position
WO2017163257A1 (en) Process for preparing pure lh-pyrazolo[3,4-d] pyrimidine derivative
US20100105887A1 (en) Process for the preparation of gemcitabine hydrochloride
EP2276740B1 (en) Improved process for preparing quinoline-3-carboxamide derivatives
US20150005518A1 (en) Process for alkynylating 16-substituted-17-keto steroids
ITMI20090908A1 (en) NEW CHEMICAL-ENAZYMATIC APPROACH TO THE SYNTHESIS OF THE PIMECROLIMUS
ES2741505T3 (en) Procedure for the preparation of abiraterone acetate and its intermediates
CA3115712A1 (en) 6-mercaptopurine nucleoside analogues
WO2022233923A1 (en) A process for synthesis of nicotinamide riboside chloride (nrcl)
EP1590353B1 (en) A process for the preparation of cefpodoxime proxetil
US20060009639A1 (en) Process for the preparation of cefpodoxime proxetil
US20110213141A1 (en) Method for preparing 1,6:2,3-dianhydro-beta-d-mannopyranose
CN111253405B (en) Preparation method of biapenem intermediate
CN111039963B (en) WXFL10203614 water-soluble analogue and synthetic method thereof
WO2017041228A1 (en) Method for preparing hexahydrofurofuranol derivative, intermediate thereof and preparation method thereof
JP2663295B2 (en) Hexadienoic acid derivative and method for producing the same
US10017515B2 (en) Stable amorphous ticagrelor and a process for its preparation
WO2022254457A1 (en) An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
US20210230155A1 (en) Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15826397

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15500616

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015826397

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015826397

Country of ref document: EP